moxetumomab pasudotox 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
mouse origin	5314	1020748-57-5

Description:

Molecule	Description
Synonyms: moxetumomab pasudotox lumoxiti CAT-8015 HA22 moxetumomab pasudotox-tdfk	Moxetumomab pasudotox-tdfk is a CD22-directed cytotoxin. Moxetumomab pasudotox-tdfk binds CD22 on the cell surface of B-cells and is internalized. Moxetumomab pasudotox -tdfk internalization results in ADP-ribosylation of elongation factor 2, inhibition of protein synthesis, and apoptotic cell death. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

moxetumomab pasudotox
lumoxiti
CAT-8015
HA22
moxetumomab pasudotox-tdfk

Moxetumomab pasudotox-tdfk is a CD22-directed cytotoxin. Moxetumomab pasudotox-tdfk binds CD22 on the cell surface of B-cells and is internalized. Moxetumomab pasudotox -tdfk internalization results in ADP-ribosylation of elongation factor 2, inhibition of protein synthesis, and apoptotic cell death.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Feb. 8, 2021	EMA	ASTRAZENECA AB
Sept. 13, 2018	FDA	ASTRAZENECA AB

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FB02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES CD22 (Clusters of Differentiation 22) inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D018796	Immunoconjugates
MeSH PA	D007155	Immunologic Factors
MeSH PA	D000922	Immunotoxins
MeSH PA	D009676	Noxae

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hairy cell leukemia	indication	118613001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
B-cell receptor CD22	Membrane receptor	P20273	CD22_HUMAN	BINDING AGENT	Kd	8.20		IUPHAR	DRUG LABEL

External reference:

ID	Source
2NDX4B6N8F	UNII
C2717021	UMLSCUI
CHEMBL1743043	ChEMBL_ID
DB12688	DRUGBANK_ID
D09932	KEGG_DRUG
9236	INN_ID
C541974	MESH_SUPPLEMENTAL_RECORD_UI
C077810	MESH_SUPPLEMENTAL_RECORD_UI
7675	IUPHAR_LIGAND_ID
017804	NDDF
781124007	SNOMEDCT_US
781155001	SNOMEDCT_US
4037930	VANDF
4037931	VANDF
3035755	PUBCHEM_CID
2099295	RXNORM
289722	MMSL
34970	MMSL
34996	MMSL
d08898	MMSL

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
LUMOXITI	HUMAN PRESCRIPTION DRUG LABEL	1	0310-4700	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 mg	INTRAVENOUS	BLA	28 sections
LUMOXITI	HUMAN PRESCRIPTION DRUG LABEL	1	0310-4700	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 mg	INTRAVENOUS	BLA	28 sections
LUMOXITI	HUMAN PRESCRIPTION DRUG LABEL	1	73380-4700	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 mg	INTRAVENOUS	BLA	31 sections